CN105343761A - Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof Download PDFInfo
- Publication number
- CN105343761A CN105343761A CN201510709522.3A CN201510709522A CN105343761A CN 105343761 A CN105343761 A CN 105343761A CN 201510709522 A CN201510709522 A CN 201510709522A CN 105343761 A CN105343761 A CN 105343761A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- myocardial infarction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 21
- 241000218176 Corydalis Species 0.000 claims abstract description 20
- 241000628997 Flos Species 0.000 claims abstract description 20
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 20
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 241001643642 Viticis Species 0.000 claims description 29
- 241000220215 Moringa Species 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 241000218628 Ginkgo Species 0.000 claims 5
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 244000194101 Ginkgo biloba Species 0.000 abstract description 15
- 208000002193 Pain Diseases 0.000 abstract description 15
- 230000036407 pain Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 230000003213 activating effect Effects 0.000 abstract description 4
- 241000304531 Allium macrostemon Species 0.000 abstract description 2
- 240000009138 Curcuma zedoaria Species 0.000 abstract description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract description 2
- 235000019509 white turmeric Nutrition 0.000 abstract description 2
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 241000202807 Glycyrrhiza Species 0.000 abstract 1
- 244000179886 Moringa oleifera Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 244000272264 Saussurea lappa Species 0.000 abstract 1
- 235000006784 Saussurea lappa Nutrition 0.000 abstract 1
- 244000063464 Vitex agnus-castus Species 0.000 abstract 1
- 235000009347 chasteberry Nutrition 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 230000017531 blood circulation Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 102000004420 Creatine Kinase Human genes 0.000 description 15
- 108010042126 Creatine kinase Proteins 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 13
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 210000004165 myocardium Anatomy 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 206010002383 Angina Pectoris Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010061623 Adverse drug reaction Diseases 0.000 description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000013146 percutaneous coronary intervention Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 244000153234 Hibiscus abelmoschus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 241000227129 Aconitum Species 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 244000295724 Allium chinense Species 0.000 description 1
- 235000016790 Allium chinense Nutrition 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 241000221040 Loranthaceae Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 241000220214 Moringaceae Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000255626 Tabanus <genus> Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001126 calcilytic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine composition for treating myocardial infarction and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from, by weight, 20-30 parts of Vitex, 18-26 parts of Rhizoma corydalis, 20-28 parts of Flos carthami, 16-24 parts of Curcuma zedoary, 14-20 parts of Salvia miltiorrhiza, 14-22 parts of Caulis polygoni multiflori, 12-16 parts of Folium ginkgo bilobae, 10-18 parts of leaf of Moringa oleifera, 8-12 parts of Allium macrostemon, 6-10 parts of Mangnolia officinalis, 6-12 parts of Radix aconiti carmichaeli, 10-16 parts of Costus root, 8-16 parts of Herba taxilli and 8-18 parts of Radix glycyrrhiza. The traditional Chinese medicine composition has efficacy of activating blood to dredge collaterals, dispersing stasis to stop pain and activating blood to nourishing heart, has remarkable effect on treating myocardial infarction and is high in clinical popularization and application value.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of myocardial infarction and preparation method thereof.
Background technology
Myocardial infarction refers to that, on the basis of coronary artery pathological changes, blood flow coronarius sharply reduces or interrupts, and makes the cardiac muscle of corresponding site occur serious and lasting ischemia and ischemic necrosis occurs.The myocardial infarction of more than 90% causes on the basis of luminal stenosis in coronary atherosclerosis, due to atheromatous plaque increase, Rupture haemorrhag, thrombosis or fixed spasm, causes tube chamber to entirely shut, and blood cannot circulate and cause.Secondly the general anterior descending branch the most often involving left coronary artery is the Circumflex branch of right coronary artery and left coronary artery.There is the patient of acute myocardial infarction, have an intense pain after often having lasting breastbone clinically, generate heat, numeration of leukocyte increases, Serum fibrosis markers raises and electrocardiogram reflecting myocardium acute injury, ischemia and necrosis series of features develop, and the symptoms such as arrhythmia, shock or heart failure can be there is, belong to the serious types of acute coronary syndrome.Most of patients a few days before acute myocardial infarction has weak, and chest is uncomfortable, and the prodromes such as cardiopalmus time movable, out of breath, irritated, angina pectoris are wherein cardinal symptom with angina pectoris.
The complication of myocardial infarction has dysfunction of papillary muscle or fracture, locular wall Aneurysm, blood vessel embolism and postmyocardial infarction syndrome etc., how to occur after one week in morbidity.The Therapeutic Principle of myocardial infarction is prevent and treat complication and reduce infarction size.Clinical treatment myocardial infarction, comprises primary percutaneous coronary intervention, thromboembolism treatment and Drug therapy.Primary percutaneous coronary intervention relapse rate is high, the main complication of thromboembolism treatment is hemorrhage, need further combined with primary percutaneous coronary intervention, and the clinical application taboos such as current clinical conventional nitroglycerin, beta-blocker, Calcilytic are more, also there is the defects such as uncertain therapeutic efficacy is fixed, drug side effect is large simultaneously.
Myocardial infarction belongs to the category such as " obstruction of qi in the chest and cardialgia ", " angina pectoris ", " precordial pain with cold limbs " of the traditional Chinese medical science, though the anosis name of motherland's medical literature is recorded, early has syndrome clearly to discuss, as " when Plain Questions hides gas method an opinion section " is said: " heart patient, chest pain, discomfort and fullness in the hypochondrium; pain between thoracic dorsal omoplate; pain in the medial sides of both arms ", " Ling Shu Miraculous Pivot or Divine Axis faint disease " is said: " angina pectoris, bluish colour of the limbs extending up to the elbows and knees; very pained; and it is dead to send out sunset, onset of disease in the evening and dying in the next morning ", be exactly the record to patients with acute myocardial infarction shock.The traditional Chinese medical science is thought, the main pathogenesis of myocardial infarction is deficiency in origin and excess in superficiality, and deficiency in origin is based on the deficiency of vital energy, the deficiency of YIN, and mark is real turbid common with the stagnation of QI, blood stasis, expectorant, and therefore its treatment is also mainly with benefiting qi and nourishing yin, and nourishing blood and promoting blood circulation, resolving depression of regulating the flow of vital energy, promoting blood circulation and stopping pain etc. are main.
The traditional Chinese medical science have accumulated certain experience at relevant diseases such as treatment obstruction of qi in the chest and cardialgia, etiology and pathogenesis understanding for myocardial infarction is more deep, meanwhile, Chinese medicine possesses the features such as the low and treating both the principal and secondary aspects of a disease of drug side effect, thus with the obvious advantage in treatment myocardial infarction.Chinese patent application 200810017389.5 discloses a kind of Chinese medicine preparation for the treatment of myocardial infarction induced by myocardial ischemia, and it is obtained by the raw material of following portions by weight: Radix Ginseng 17-22 part, water baby 8-12 part, Fructus Schisandrae Chinensis 8-12 part, Radix Aconiti Lateralis Preparata 8-12 part, Radix Salviae Miltiorrhizae 8-12 part, Semen Platycladi 18-22 part, Tabanus 8-12 part, Rhizoma Pinelliae 8-12 part, Radix Notoginseng 8-12 part, Rhizoma Chuanxiong 8-12 part, Moschus 0.8-1.2 part, Fructus Trichosanthis 13-17 part, Bulbus Allii Macrostemonis 13-17 part.This Chinese medicine preparation based on QI invigorating, invigorate blood circulation, eliminating phlegm, the myocardial infarction caused in conjunction with western medical treatment myocardial ischemia obviously can reduce the incidence rate of the complication such as arrhythmia, thromboembolism, but it needs and other drug partner treatment, and selected cost of material is high, is not easy to apply.
Myocardial infarction is still a large difficult point of angiocardiology Therapy study at present.Chinese traditional treatment myocardial infarction, has low drug side effect, the features such as treating both the principal and secondary aspects of a disease, has a extensive future, and seeks a kind of rapid-action, good effect, efficacy stability, and cost medicine that is low and that be easy to the treatment myocardial infarction promoted the use of is this area urgent problem.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition for the treatment of myocardial infarction, this Chinese medicine composition has promoting blood circulation to remove obstruction in the collateral, eliminating stasis to stop pain, invigorates blood circulation and to nourish heart and benefiting QI and nourishing blood effect, possess therapeutic effect significantly, efficacy stability, treating both the principal and secondary aspects of a disease and be easy to advantages such as applying.In addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use finished product preparation under the prerequisite ensureing curative effect by this Chinese medicine.
Chinese medicine composition of the present invention is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 20-30 part, Rhizoma Corydalis 18-26 part, Flos Carthami 20-28 part, Rhizoma Curcumae 16-24 part, Radix Salviae Miltiorrhizae 14-20 part, Caulis Polygoni Multiflori 14-22 part, Folium Ginkgo 12-16 part, leaf of Moringa 10-18 part, Bulbus Allii Macrostemonis 8-12 part, Cortex Magnoliae Officinalis 6-10 part, Radix Aconiti Lateralis Preparata 6-12 part, Radix Aucklandiae 10-16 part, Herba Taxilli 8-16 part and Radix Glycyrrhizae 8-18 part.
Further, described Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 20 parts, Rhizoma Corydalis 18 parts, 20 parts, Flos Carthami, Rhizoma Curcumae 16 parts, Radix Salviae Miltiorrhizae 14 parts, Caulis Polygoni Multiflori 14 parts, Folium Ginkgo 12 parts, leaf of Moringa 10 parts, Bulbus Allii Macrostemonis 8 parts, Cortex Magnoliae Officinalis 6 parts, Radix Aconiti Lateralis Preparata 6 parts, the Radix Aucklandiae 10 parts, Herba Taxilli 8 parts and 8 parts, Radix Glycyrrhizae.
Further, described Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 30 parts, Rhizoma Corydalis 26 parts, 28 parts, Flos Carthami, Rhizoma Curcumae 24 parts, Radix Salviae Miltiorrhizae 20 parts, Caulis Polygoni Multiflori 22 parts, Folium Ginkgo 16 parts, leaf of Moringa 18 parts, Bulbus Allii Macrostemonis 12 parts, Cortex Magnoliae Officinalis 10 parts, Radix Aconiti Lateralis Preparata 12 parts, the Radix Aucklandiae 16 parts, Herba Taxilli 16 parts and 18 parts, Radix Glycyrrhizae.
Further, described Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 26 parts, Rhizoma Corydalis 22 parts, 24 parts, Flos Carthami, Rhizoma Curcumae 20 parts, Radix Salviae Miltiorrhizae 16 parts, Caulis Polygoni Multiflori 18 parts, Folium Ginkgo 14 parts, leaf of Moringa 14 parts, Bulbus Allii Macrostemonis 10 parts, Cortex Magnoliae Officinalis 8 parts, Radix Aconiti Lateralis Preparata 8 parts, the Radix Aucklandiae 12 parts, Herba Taxilli 14 parts and 14 parts, Radix Glycyrrhizae.
Present invention also offers the preparation method of described Chinese medicine composition, mainly comprise the following steps:
S1 gets Herba Viticis Cannabifoliae and pulverizes, coarse powder is placed in supercritical carbon dioxide extraction apparatus, adding above-mentioned coarse powder total amount 30-45% volume fraction is the ethanol of 60-85%, regulation and control carbon dioxide flow is 15-20L/h, extracting pressure is 15-20MPa, extraction temperature is 40-60 DEG C, and extraction time is 1.5-2h, and decompression separation obtains Herba Viticis Cannabifoliae extract;
S2 gets Rhizoma Corydalis, Radix Salviae Miltiorrhizae, Cortex Magnoliae Officinalis, leaf of Moringa and Folium Ginkgo, pulverize, the 4-6 times of concentration adding above-mentioned coarse powder gross weight is the ethanol of 65%-75%, reflux, extract, 2-3 time, and each return time is 2-3h, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, drying under reduced pressure, cross 80-100 mesh sieve after pulverizing, obtain extractum fine powder A;
S3 gets Rhizoma Curcumae, Flos Carthami, Radix Aconiti Lateralis Preparata, the Radix Aucklandiae, Herba Taxilli, Bulbus Allii Macrostemonis, Caulis Polygoni Multiflori and Radix Glycyrrhizae, pulverize, add the soak by water 3-4h of above-mentioned coarse powder gross weight 6-8 times amount, decoct 2-3 time, filter, merging filtrate, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, drying under reduced pressure, crosses 80-100 mesh sieve after pulverizing, obtains extractum fine powder B;
The extractum fine powder B that the extractum fine powder A that Herba Viticis Cannabifoliae extract and step S2 that step S1 obtains by S4 obtain and step S3 obtains mixes, and dry, pulverize, to obtain final product.
Utilize modern general Chinese medicine preparation technology, Chinese medicine composition of the present invention can be made into the finished product preparation of clinical needs, as dosage forms such as granule, pill, powder, tablet or capsules.
Source, the nature and flavor of Chinese medicine composition of the present invention Chinese crude drug used, return through and effect:
Herba Viticis Cannabifoliae: this product is the stem of Verenaceae Herba Viticis Cannabifoliae.Acrid in the mouth; Micro-hardship; Property is put down; Return lung, liver, spleen, stomach warp; Expelling pathogenic wind from the body surface; Reducing swelling and alleviating pain.
Rhizoma Corydalis: this product is the dry tuber of papaveraceae plant corydalis.Acrid in the mouth, hardship, warm in nature; Return liver, spleen channel; Promoting blood circulation to remove blood stasis, regulating QI to relieve pain.
Flos Carthami: this product is the dried floral of feverfew Flos Carthami.Acrid in the mouth, warm in nature; GUIXIN, Liver Channel; Promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain.
Rhizoma Curcumae: this product is the dry rhizome of zingiberaceous plant Rhizoma Curcumae, Guangxi zedoary or RADIX CURCUMAE.Acrid in the mouth, hardship, warm in nature; Return liver, spleen channel; Circulation of qi promoting removing blood stasis, removing food stagnancy pain relieving.
Radix Salviae Miltiorrhizae: this product is the dry root and rhizome of labiate Radix Salviae Miltiorrhizae.Bitter in the mouth, cold nature; GUIXIN, Liver Channel; Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, calms the nerves peaceful tired.
Caulis Polygoni Multiflori: this product is rattan or the leaf bine stem of polygonum multiflorum thunb.Sweet in the mouth, bitter in the mouth, property is put down; GUIXIN, Liver Channel; Nourish heart, calm the nerves, dredging collateral, dispel the wind.
Folium Ginkgo: this product is the blade of Ginkgoaceae plant Ginkgo biloba.Bitter in the mouth, sweet, puckery, property is put down; GUIXIN, lung, spleen channel; Invigorate blood circulation and nourish heart, astringing intestine to stop diarrhea of astringing the lung.
Leaf of Moringa: this product is the dried leaves of Moringaceae plant Moringa.Bitter in the mouth, slightly warm in nature; Leaf of Moringa has the effects such as blood sugar lowering, blood fat reducing, blood pressure lowering, antitumor, antioxidation and enhancing immunity.
Bulbus Allii Macrostemonis: this product is the dry bulb of liliaceous plant Allium macrostemon or Chinese onion.Acrid in the mouth, hardship, warm in nature; Return lung, stomach, large intestine channel; Activating YANG and eliminating stagnation, circulation of qi promoting intestinal stasis relieving.
Cortex Magnoliae Officinalis: this product is the dry dried bark of Magnoliacea plant Cortex Magnoliae Officinalis or magnolia officinalis rehd.et wils.var.biloba rehd.et wils., root bark and branch skin.Bitter in the mouth, pungent, warm in nature; Return spleen, stomach, lung, large intestine channel; Warming the middle warmer and descending qi, dampness expectorant.
Radix Aconiti Lateralis Preparata: this product is the processed goods of the daughter root of ranunculaceae plant Aconitum carmichjaelii Debx..Acrid in the mouth, sweet, hot in nature; GUIXIN, kidney, spleen channel; Recuperating depleted YANG and rescuing the patient from collapse, mends fire supporing yang, by wind-cold damp pathogen.
The Radix Aucklandiae: this product is the dry root of the feverfew Radix Aucklandiae.Acrid in the mouth, hardship, warm in nature; Return spleen, stomach, large intestine, three burnt, gallbladder meridians; Promoting the circulation of QI to relieve pain, strengthening the spleen to promote digestion.
Herba Taxilli: this product is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli.Bitter in the mouth, sweet, property is put down; Return liver, kidney channel; Invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, the meridian dredging, beneficial blood, antiabortive.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L..Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The prescription analysis of medicament composing prescription of the present invention:
Medicament composing prescription of the present invention with Herba Viticis Cannabifoliae, Rhizoma Corydalis Flos Carthami for monarch drug, promoting blood circulation to remove blood stasis, the meridian dredging, regulating QI to relieve pain; With Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Caulis Polygoni Multiflori and Folium Ginkgo for ministerial drug, removing blood stasis circulation of qi promoting, inducing menstruation to relieve menalgia, invigorates blood circulation and nourishes heart, and calms the nerves peaceful tired; With leaf of Moringa, Bulbus Allii Macrostemonis, Cortex Magnoliae Officinalis, Radix Aconiti Lateralis Preparata, the Radix Aucklandiae and Herba Taxilli for adjuvant drug, warming middle-JIAO to promote flow of QI, the liver and the kidney tonifying, activating YANG and eliminating stagnation, circulation of qi promoting intestinal stasis relieving, blood sugar lowering, blood fat and blood pressure; With Radix Glycyrrhizae for making medicine, invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription, makes all medicines arrange in pairs or groups, synergism, reaches promoting blood circulation to remove obstruction in the collateral jointly, and eliminating stasis to stop pain is invigorated blood circulation and nourished heart, the liver and the kidney tonifying, blood fat reducing, effect of blood sugar lowering and blood pressure lowering, has very significant therapeutic effect to myocardial infarction.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, and namely above-mentioned Chinese medicine composition is preparing the purposes in myocardial infarction medicine.Creatine kinase (CK), aspartate amino transferase (AST) and lactic acid dehydrogenase (LDH) are the protease be present in myocardial cell, when cell injury or necrosis, CK, AST, LDH just can be discharged into blood in cell, therefore measure serum CK, index that AST, LDH can be used as reflecting myocardium degree of necrosis.Chinese medicine composition of the present invention shows the experimentation of myocardial infarction model rat, Chinese medicine composition of the present invention significantly can improve the content of CK, AST, LDH in the serum of myocardial infarction model rat, compare with positive controls, Chinese medicine composition A group high dose group of the present invention, the height of B group high dose group and C group, the action effect of middle dosage group are all significantly better than positive controls.This illustrates traditional Chinese medicine composition for treating myocardial infarction Be very effective of the present invention, and clinical value is high.
Compared with prior art, Chinese medicine composition of the present invention has following technical advantage:
(1) Chinese medicine composition medical material of the present invention and dose compatibility science, synergism is strong, has significant promoting blood circulation to remove obstruction in the collateral, eliminating stasis to stop pain, and invigorate blood circulation and nourish heart and effect of the liver and the kidney tonifying, treatment myocardial infarction is with strong points, and effect comprehensively.
(2) pharmacological testing proves; Chinese medicine composition of the present invention significantly can reduce the content of lactic acid dehydrogenase (LDH) in myocardial infarction model rat blood serum, creatine kinase (CK) and paddy transaminase (AST); thus prove that it significantly can improve the degree of myocardial necrosis; to myocardial ischemia, there is significant protective effect, treatment myocardial infarction Be very effective.
(3) Chinese medicine composition of the present invention is pure Chinese medicinal preparation, and drug side effect is low, and clinical to be used for the treatment of myocardial infarction rapid-action, good effect, also has efficacy stability simultaneously and is easy to advantages such as applying.
Detailed description of the invention
Below will further describe the present invention by specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, be included within the scope of the present invention.
embodiment 1
The embodiment of the present invention 1 Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 20 parts, Rhizoma Corydalis 18 parts, 20 parts, Flos Carthami, Rhizoma Curcumae 16 parts, Radix Salviae Miltiorrhizae 14 parts, Caulis Polygoni Multiflori 14 parts, Folium Ginkgo 12 parts, leaf of Moringa 10 parts, Bulbus Allii Macrostemonis 8 parts, Cortex Magnoliae Officinalis 6 parts, Radix Aconiti Lateralis Preparata 6 parts, the Radix Aucklandiae 10 parts, Herba Taxilli 8 parts and 8 parts, Radix Glycyrrhizae.
Preparation method is as follows:
S1 gets Herba Viticis Cannabifoliae and pulverizes, coarse powder is placed in supercritical carbon dioxide extraction apparatus, adding above-mentioned coarse powder total amount 30% volume fraction is the ethanol of 60%, regulation and control carbon dioxide flow is 15L/h, extracting pressure is 15MPa, extraction temperature is 40 DEG C, and extraction time is 1.5h, and decompression separation obtains Herba Viticis Cannabifoliae extract;
S2 gets Rhizoma Corydalis, Radix Salviae Miltiorrhizae, Cortex Magnoliae Officinalis, leaf of Moringa and Folium Ginkgo, pulverize, the 4 times of concentration adding above-mentioned coarse powder gross weight are the ethanol of 65%, reflux, extract, 2 times, and each return time is 2h, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 60 DEG C of environment is the extractum of 1.20, drying under reduced pressure, cross 80 mesh sieves after pulverizing, obtain extractum fine powder A;
S3 gets Rhizoma Curcumae, Flos Carthami, Radix Aconiti Lateralis Preparata, the Radix Aucklandiae, Herba Taxilli, Bulbus Allii Macrostemonis, Caulis Polygoni Multiflori and Radix Glycyrrhizae, pulverize, add the soak by water 3h of above-mentioned coarse powder gross weight 6 times amount, decoct 2 times, filter, merging filtrate, being evaporated to relative density under 60 DEG C of environment is the extractum of 1.20, drying under reduced pressure, crosses 80 mesh sieves after pulverizing, obtains extractum fine powder B;
The extractum fine powder B that the extractum fine powder A that Herba Viticis Cannabifoliae extract and step S2 that step S1 obtains by S4 obtain and step S3 obtains mixes, and dry, pulverize, adds corresponding adjuvant, make granule.
embodiment 2
The embodiment of the present invention 2 Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 30 parts, Rhizoma Corydalis 26 parts, 28 parts, Flos Carthami, Rhizoma Curcumae 24 parts, Radix Salviae Miltiorrhizae 20 parts, Caulis Polygoni Multiflori 22 parts, Folium Ginkgo 16 parts, leaf of Moringa 18 parts, Bulbus Allii Macrostemonis 12 parts, Cortex Magnoliae Officinalis 10 parts, Radix Aconiti Lateralis Preparata 12 parts, the Radix Aucklandiae 16 parts, Herba Taxilli 16 parts and 18 parts, Radix Glycyrrhizae.
Preparation method is as follows:
S1 gets Herba Viticis Cannabifoliae and pulverizes, coarse powder is placed in supercritical carbon dioxide extraction apparatus, adding above-mentioned coarse powder total amount 40% volume fraction is the ethanol of 75%, regulation and control carbon dioxide flow is 18L/h, extracting pressure is 16MPa, extraction temperature is 50 DEG C, and extraction time is 1.5h, and decompression separation obtains Herba Viticis Cannabifoliae extract;
S2 gets Rhizoma Corydalis, Radix Salviae Miltiorrhizae, Cortex Magnoliae Officinalis, leaf of Moringa and Folium Ginkgo, pulverize, the 5 times of concentration adding above-mentioned coarse powder gross weight are the ethanol of 70%, reflux, extract, 2 times, and each return time is 2h, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 62 DEG C of environment is the extractum of 1.23, drying under reduced pressure, cross 80 mesh sieves after pulverizing, obtain extractum fine powder A;
S3 gets Rhizoma Curcumae, Flos Carthami, Radix Aconiti Lateralis Preparata, the Radix Aucklandiae, Herba Taxilli, Bulbus Allii Macrostemonis, Caulis Polygoni Multiflori and Radix Glycyrrhizae, pulverize, add the soak by water 3h of above-mentioned coarse powder gross weight 7 times amount, decoct 2 times, filter, merging filtrate, being evaporated to relative density under 62 DEG C of environment is the extractum of 1.23, drying under reduced pressure, crosses 80 mesh sieves after pulverizing, obtains extractum fine powder B;
The extractum fine powder B that the extractum fine powder A that Herba Viticis Cannabifoliae extract and step S2 that step S1 obtains by S4 obtain and step S3 obtains mixes, and dry, pulverize, adds corresponding adjuvant, make tablet.
embodiment 3
The embodiment of the present invention 3 Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 26 parts, Rhizoma Corydalis 22 parts, 24 parts, Flos Carthami, Rhizoma Curcumae 20 parts, Radix Salviae Miltiorrhizae 16 parts, Caulis Polygoni Multiflori 18 parts, Folium Ginkgo 14 parts, leaf of Moringa 14 parts, Bulbus Allii Macrostemonis 10 parts, Cortex Magnoliae Officinalis 8 parts, Radix Aconiti Lateralis Preparata 8 parts, the Radix Aucklandiae 12 parts, Herba Taxilli 14 parts and 14 parts, Radix Glycyrrhizae.
Preparation method is as follows:
S1 gets Herba Viticis Cannabifoliae and pulverizes, coarse powder is placed in supercritical carbon dioxide extraction apparatus, adding above-mentioned coarse powder total amount 45% volume fraction is the ethanol of 85%, regulation and control carbon dioxide flow is 20L/h, extracting pressure is 20MPa, extraction temperature is 60 DEG C, and extraction time is 2h, and decompression separation obtains Herba Viticis Cannabifoliae extract;
S2 gets Rhizoma Corydalis, Radix Salviae Miltiorrhizae, Cortex Magnoliae Officinalis, leaf of Moringa and Folium Ginkgo, pulverize, the 6 times of concentration adding above-mentioned coarse powder gross weight are the ethanol of 75%, reflux, extract, 3 times, and each return time is 3h, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 65 DEG C of environment is the extractum of 1.25, drying under reduced pressure, cross 100 mesh sieves after pulverizing, obtain extractum fine powder A;
S3 gets Rhizoma Curcumae, Flos Carthami, Radix Aconiti Lateralis Preparata, the Radix Aucklandiae, Herba Taxilli, Bulbus Allii Macrostemonis, Caulis Polygoni Multiflori and Radix Glycyrrhizae, pulverize, add the soak by water 4h of above-mentioned coarse powder gross weight 8 times amount, decoct 3 times, filter, merging filtrate, being evaporated to relative density under 65 DEG C of environment is the extractum of 1.25, drying under reduced pressure, crosses 100 mesh sieves after pulverizing, obtains extractum fine powder B;
The extractum fine powder B that the extractum fine powder A that Herba Viticis Cannabifoliae extract and step S2 that step S1 obtains by S4 obtain and step S3 obtains mixes, and dry, pulverize, adds corresponding adjuvant, make capsule.
chinese medicine composition pharmacodynamic study of the present invention:
test one: Chinese medicine composition of the present invention is to the experimentation of myocardial infarction model rat
1, test principle: lactic acid dehydrogenase (LDH), creatine kinase (CK) and paddy transaminase (AST) are three kinds of main myocardium enzyme.Under normal circumstances, the content of myocardium enzyme in serum is very low, when myocardial ischemia and necrosis or permeability of cell membrane increase, myocardium enzyme is just discharged into blood from myocardial cell, different according to myocardium institute degree of impairment, the amplitude that in serum, enzyme raises is also different, therefore can come the generation of reflecting myocardium infarction and the size of focus by the changes of contents of LDH, CK, AST in serum.The assay of myocardium enzyme is usually used in the auxiliary diagnosis of myocardial infarction clinically.This test proves its therapeutic effect to myocardial infarction by research Chinese medicine composition of the present invention to the impact of LDH, CK and AST level in myocardial infarction model rat blood serum.
2, experimental animal: SPF level male SD rat 130, in 18 ~ 20 week age, body weight 230 ~ 280g, is divided into 13 groups at random, often organizes 10.
3, trial drug and dosage regimen:
A group: trial drug is the granule of the embodiment of the present invention 1, is deployed into water the solution that concentration is 0.6g/ml, 0.4g/ml and 0.2g/ml, for subsequent use.Get 3 groups of myocardial infarction model rats, be labeled as A group high dose group (1.2g/kg), middle dosage group (0.8g/kg) and low dose group (0.4g/kg), high dose group concentration is the drug solution administration of 0.6g/ml, middle dosage group concentration is the drug solution of 0.4g/ml, low dose group concentration is the drug solution of 0.2g/ml, according to dosage every day gavage 1 time, successive administration 14 days.
B group: trial drug is the tablet of the embodiment of the present invention 2, and dosage regimen is with A group.
C group: trial drug is the capsule of the embodiment of the present invention 3, and dosage regimen is with A group.
Positive controls: positive control drug is the happy capsule of Moschus heart and brain (the accurate word Z20050054 of traditional Chinese medicines accurate word traditional Chinese medicines, great Jun Pharmaceutical limited company of Jilin Province), remove photoresist and content water is deployed into after softgel shell the solution of 0.6g/ml, get 1 group of myocardial infarction model rat, by dosage gastric infusion every day 1 time of 1.2g/kg, successive administration 14 days.
Model control group: get 1 group of myocardial infarction model rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 14 days.
Sham operated rats: get 1 group of rat, isometric(al) normal saline gavage every day 1 time after sham-operation, continuous gavage 14 days.
Normal group: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 14 days.
4, the foundation of rat model of myocardial infarction
Rat pre-operative anxiety 12h, 3% pentobarbital sodium (40mg/kg) intraperitoneal injection of anesthesia, back of the body position is fixed, and connects limb lead, record rat surface electrocardiogram.Cervical region and front depilation, iodophor disinfection, toy assisted mechanical ventilator is connected through tracheal intubation, tidal volume 3ml/100g rat, respiratory quotient 3:1, respiratory frequency 70 times/min, successively breast is opened through left front para T the 3rd, 4 intercostals, expose heart, cut off pericardium, having a common boundary at left auricle and pulmonary conus slightly descends 1 ~ 2mm place 6-0 silk thread following coronary artery occlusion anterior descending branch to make myocardial infarction model, and myocardium color below the visible ligature of naked eyes loses color and heartbeat weakens, and is modelling success criterion.Rapidly heart is put back to thoracic cavity after ligation, extrude breast intracavity gas subsequently, layer-by-layer suture closes breast.Postoperative 30min Rat Ecg occurs that lead R wave-amplitude step-down, ST section of II, III, AVL, AVF is raised, thus Confirming model is successfully set up further.Rats in sham-operated group operation method is the same, and silk thread passes but not ligation from coronary artery.Postoperative every rat lumbar injection every day penicillin 400,000 unit, continuously injection 3 days, prevention infection.
5, result of the test: after administration terminates, carries out heart extracting blood by after rat anesthesia, and measure the content of LDH, CK, AST in serum, result is as shown in table 1
Table 1 Chinese medicine composition of the present invention is on the impact of myocardial infarction model rat
Note: compare with Normal group,
△ △p0.01; Compare with model control group,
*p0.05,
*p0.01; Compare with positive controls,
#p0.05,
##p0.01.
6, conclusion (of pressure testing)
Test data shows, compare with Normal group, LDH, CK, AST content of rats in sham-operated group is without the change of significance, and LDH, CK, AST content of model group rats all pole significance increase (P0.01), consistent with the Serum fibrosis markers changes of contents of human myocardium's infarction disease, can be used for research Chinese medicine composition of the present invention to the therapeutic effect of myocardial infarction.
Compare with model control group, Chinese medicine composition of the present invention significantly can improve the Serum fibrosis markers content of myocardial infarction model rat, wherein A group high dose group, the height of B group high dose group and C group, the action effect of middle dosage group are all significantly better than positive controls (P0.05 or P0.01), and other dosage groups also can reduce the content of LDH, CK, AST in rat blood serum to a certain extent.This illustrates that Chinese medicine composition of the present invention is remarkable to the therapeutic effect of myocardial infarction, can be used for the clinical treatment of myocardial infarction.
Claims (7)
1. treat a Chinese medicine composition for myocardial infarction, it is characterized in that, described Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 20-30 part, Rhizoma Corydalis 18-26 part, Flos Carthami 20-28 part, Rhizoma Curcumae 16-24 part, Radix Salviae Miltiorrhizae 14-20 part, Caulis Polygoni Multiflori 14-22 part, Folium Ginkgo 12-16 part, leaf of Moringa 10-18 part, Bulbus Allii Macrostemonis 8-12 part, Cortex Magnoliae Officinalis 6-10 part, Radix Aconiti Lateralis Preparata 6-12 part, Radix Aucklandiae 10-16 part, Herba Taxilli 8-16 part and Radix Glycyrrhizae 8-18 part.
2. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 20 parts, Rhizoma Corydalis 18 parts, 20 parts, Flos Carthami, Rhizoma Curcumae 16 parts, Radix Salviae Miltiorrhizae 14 parts, Caulis Polygoni Multiflori 14 parts, Folium Ginkgo 12 parts, leaf of Moringa 10 parts, Bulbus Allii Macrostemonis 8 parts, Cortex Magnoliae Officinalis 6 parts, Radix Aconiti Lateralis Preparata 6 parts, the Radix Aucklandiae 10 parts, Herba Taxilli 8 parts and 8 parts, Radix Glycyrrhizae.
3. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 30 parts, Rhizoma Corydalis 26 parts, 28 parts, Flos Carthami, Rhizoma Curcumae 24 parts, Radix Salviae Miltiorrhizae 20 parts, Caulis Polygoni Multiflori 22 parts, Folium Ginkgo 16 parts, leaf of Moringa 18 parts, Bulbus Allii Macrostemonis 12 parts, Cortex Magnoliae Officinalis 10 parts, Radix Aconiti Lateralis Preparata 12 parts, the Radix Aucklandiae 16 parts, Herba Taxilli 16 parts and 18 parts, Radix Glycyrrhizae.
4. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Herba Viticis Cannabifoliae 26 parts, Rhizoma Corydalis 22 parts, 24 parts, Flos Carthami, Rhizoma Curcumae 20 parts, Radix Salviae Miltiorrhizae 16 parts, Caulis Polygoni Multiflori 18 parts, Folium Ginkgo 14 parts, leaf of Moringa 14 parts, Bulbus Allii Macrostemonis 10 parts, Cortex Magnoliae Officinalis 8 parts, Radix Aconiti Lateralis Preparata 8 parts, the Radix Aucklandiae 12 parts, Herba Taxilli 14 parts and 14 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition as described in as arbitrary in claim 1-4, it is characterized in that, described Chinese medicine composition is made into granule, pill, powder, tablet or capsule.
6. the preparation method of the Chinese medicine composition as described in as arbitrary in claim 1-4, it is characterized in that, described preparation method comprises the following steps:
S1 gets Herba Viticis Cannabifoliae and pulverizes, coarse powder is placed in supercritical carbon dioxide extraction apparatus, adding above-mentioned coarse powder total amount 30-45% volume fraction is the ethanol of 60-85%, regulation and control carbon dioxide flow is 15-20L/h, extracting pressure is 15-20MPa, extraction temperature is 40-60 DEG C, and extraction time is 1.5-2h, and decompression separation obtains Herba Viticis Cannabifoliae extract;
S2 gets Rhizoma Corydalis, Radix Salviae Miltiorrhizae, Cortex Magnoliae Officinalis, leaf of Moringa and Folium Ginkgo, pulverize, the 4-6 times of concentration adding above-mentioned coarse powder gross weight is the ethanol of 65%-75%, reflux, extract, 2-3 time, and each return time is 2-3h, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, drying under reduced pressure, cross 80-100 mesh sieve after pulverizing, obtain extractum fine powder A;
S3 gets Rhizoma Curcumae, Flos Carthami, Radix Aconiti Lateralis Preparata, the Radix Aucklandiae, Herba Taxilli, Bulbus Allii Macrostemonis, Caulis Polygoni Multiflori and Radix Glycyrrhizae, pulverize, add the soak by water 3-4h of above-mentioned coarse powder gross weight 6-8 times amount, decoct 2-3 time, filter, merging filtrate, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, drying under reduced pressure, crosses 80-100 mesh sieve after pulverizing, obtains extractum fine powder B;
The extractum fine powder B that the extractum fine powder A that Herba Viticis Cannabifoliae extract and step S2 that step S1 obtains by S4 obtain and step S3 obtains mixes, and dry, pulverize, to obtain final product.
7. the purposes of Chinese medicine composition as claimed in claim 1 in preparation treatment myocardial infarction medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510709522.3A CN105343761A (en) | 2015-10-28 | 2015-10-28 | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510709522.3A CN105343761A (en) | 2015-10-28 | 2015-10-28 | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105343761A true CN105343761A (en) | 2016-02-24 |
Family
ID=55319920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510709522.3A Pending CN105343761A (en) | 2015-10-28 | 2015-10-28 | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343761A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105748931A (en) * | 2016-04-14 | 2016-07-13 | 青岛市黄岛区中医医院 | Traditional Chinese medicine for treating acute myocardial infraction combined with shock and preparation method |
| CN105901834A (en) * | 2016-07-05 | 2016-08-31 | 江苏大学 | Shoe pad for improving sleep and preparation method thereof |
-
2015
- 2015-10-28 CN CN201510709522.3A patent/CN105343761A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 梁艳芳: "中西医结合治疗急性心肌梗塞38例", 《辽宁中医药杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105748931A (en) * | 2016-04-14 | 2016-07-13 | 青岛市黄岛区中医医院 | Traditional Chinese medicine for treating acute myocardial infraction combined with shock and preparation method |
| CN105901834A (en) * | 2016-07-05 | 2016-08-31 | 江苏大学 | Shoe pad for improving sleep and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104940740A (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof | |
| CN102512644B (en) | Traditional Chinese medicine composition for removing freckles and nourishing skin and preparation method for same | |
| CN105833229A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN106334171A (en) | Traditional Chinese medicine preparation for repairing liver damage and preparation method thereof | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN102988938A (en) | Traditional Chinese medicine composition for treating arrhythmia or atrial fibrillation and preparation method thereof | |
| CN102526628B (en) | Medicinal composition for treating myocardial infarction | |
| CN1966050A (en) | Medicament for treating heart disease and preparation process thereof | |
| CN105878921A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105233157A (en) | Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction | |
| CN104940279A (en) | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction | |
| CN105148211A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparing method thereof | |
| CN105362610A (en) | Traditional Chinese medicine composition for treating coronary artery diseases | |
| CN105381175A (en) | Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases | |
| CN105079319A (en) | Prescription for treating sciatica | |
| CN105343508A (en) | Method for preparing traditional Chinese medicine composition for treating climacteric syndrome | |
| CN105125860A (en) | Preparation for effectively treating osteoporosis | |
| CN104096212A (en) | Traditional Chinese medicine application for treating myocardial infarction and application for same | |
| CN104491316A (en) | Traditional Chinese medicine preparation for treating middle-warmer energy insufficiency type prostate hyperplasia | |
| CN104491602A (en) | Traditional Chinese medicine for treating chronic heart failure, premature beat and arrhythmia and preparation method thereof | |
| CN104510935A (en) | Chinese medicinal mixture for treatment of upper-jiao heat stagnation type head hyperhidrosis | |
| CN111329953A (en) | Traditional Chinese medicine composition for treating climacteric syndrome and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160224 |